Wegovy vs Mounjaro for Weight Loss

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Wegovy vs Mounjaro for weight loss — Wegovy vs Mounjaro for Weight Loss. Read on for an evidence-backed guide covering everything you need to know.

Hero Intro

Wegovy vs Mounjaro for weight loss — in June 2021, the FDA approved semaglutide 2.4 mg — brand name Wegovy — for chronic weight management, and the obesity medicine landscape shifted overnight. Eleven months later, tirzepatide — brand name Mounjaro — received its first approval for type 2 diabetes, and the follow-up SURMOUNT-1 trial in obesity showed weight loss numbers the field had never seen from a medication: 20.9% of body weight at the highest dose.

Wegovy vs Mounjaro for weight loss — suddenly the question was no longer “should I take a GLP-1 medication?” but rather, “Wegovy vs Mounjaro for weight loss — which one is right for me?” Two years later, with both drugs firmly established, Mounjaro now carrying a cardiovascular risk reduction indication, and Wegovy available in both injectable and oral tablet forms, that question has only become more complex — and more important.

Wegovy vs Mounjaro for weight loss — this guide will give you the clearest, most evidence-backed comparison available. By the end, you will understand the one molecular difference between these two drugs that explains almost everything — from how much weight you will likely lose to which side effects might hit hardest — and you will know which conversation to have with your doctor.

Wegovy vs Mounjaro for weight loss — here is the number most comparison articles skip: in the only direct head-to-head trial data we have, tirzepatide outperformed semaglutide on weight loss at every dose level. But there is a caveat — and it matters more than the headline number.

• What Are Wegovy and Mounjaro?
• How They Work: The One Difference That Changes Everything
• Wegovy vs Mounjaro for Weight Loss: The Real Results
• Wegovy vs Mounjaro for Weight Loss: Safety & Side Effects
• What Does the Research Say?
• Dosing & Administration: Injections vs Pills
• Wegovy vs Mounjaro for Weight Loss: Cost & Access
• Which One Fits Your Situation?
• Frequently Asked Questions
• The Bottom Line

What Are Wegovy and Mounjaro?

Wegovy vs Mounjaro for weight loss — wegovy is manufactured by Novo Nordisk and received FDA approval for weight management in June 2021. Its active ingredient, semaglutide, is a synthetic analogue of the human GLP-1 hormone, designed to resist breakdown in the body for a full week. In addition to the original injectable form, Wegovy became available as a once-daily oral tablet in 2026 — the first oral GLP-1 medication approved specifically for weight management.

Wegovy vs Mounjaro for weight loss — mounjaro is manufactured by Eli Lilly and received its initial FDA approval for type 2 diabetes in May 2022, followed by approval for weight management (under the brand name Zepbound) in November 2023. Its active ingredient, tirzepatide, is a first-in-class dual agonist: it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual mechanism is the single most important difference in the Wegovy vs Mounjaro for weight loss comparison — and it is the reason for tirzepatide’s superior weight loss results.

Wegovy vs Mounjaro for weight loss — both drugs are prescription-only medications administered by subcutaneous injection once weekly, using pre-filled single-dose pens. Wegovy is also available as a once-daily oral tablet. Both require gradual dose escalation over several weeks to minimise gastrointestinal side effects, and both are intended for long-term use alongside a reduced-calorie diet and increased physical activity.

How They Work: The One Difference That Changes Everything

Here is an analogy that makes the mechanism difference concrete: imagine appetite regulation is like controlling the temperature in a house. Semaglutide (Wegovy) turns down the thermostat — it reduces the set point for hunger in your brain. Tirzepatide (Mounjaro) turns down the thermostat and also opens the windows — it suppresses appetite while simultaneously improving how your body handles the calories it does consume through enhanced insulin sensitivity and potentially increased energy expenditure.

Both medications:

• Slow gastric emptying, making you feel physically fuller for longer after eating
• Act on appetite centres in the hypothalamus to reduce hunger and food cravings
• Improve insulin secretion in a glucose-dependent manner (lowering blood sugar only when it is actually elevated)
• Reduce “food noise” — the constant, intrusive thoughts about eating that many people with obesity experience

Tirzepatide additionally:

• Activates GIP receptors, which appears to enhance the insulin-sensitising and appetite-suppressing effects beyond what GLP-1 activation alone can achieve
• May influence fat metabolism and energy expenditure through GIP pathways — though the precise mechanisms in humans are still being researched

This dual action is elegant in theory. In practice, it produces the weight loss numbers you will see in the next section.

Wegovy vs Mounjaro for Weight Loss: The Real Results

Here is what these numbers mean for you, in practical terms. If you weigh 220 pounds:

• Wegovy (injectable, 2.4 mg) might help you lose about 33 pounds (14.9%)
• Mounjaro (15 mg) might help you lose about 46 pounds (20.9%)
• Mounjaro at just 5 mg — the lowest maintenance dose — produces results similar to Wegovy at its maximum

But — and this is the caveat — these numbers come from different clinical trials with different populations, and the trials were not designed as head-to-head comparisons in obesity. The only direct head-to-head data comes from the SURPASS-2 trial, which enrolled patients with type 2 diabetes — not the general obesity population. In that trial, tirzepatide consistently outperformed semaglutide, but the absolute weight loss was lower across the board (because people with diabetes typically lose less weight on GLP-1s).

A dedicated head-to-head trial (SURMOUNT-5) comparing tirzepatide to semaglutide in people with obesity without diabetes is underway, with results expected in 2025–2026. That trial will provide the most definitive answer to the Wegovy vs Mounjaro for weight loss question.

Wegovy vs Mounjaro for Weight Loss: Safety & Side Effects

The side-effect profiles of Wegovy vs Mounjaro for weight loss overlap significantly — gastrointestinal effects dominate for both drugs and are dose-dependent. The key clinical observation: tirzepatide appears to have a slightly more favourable GI tolerability profile, with nausea, diarrhoea, vomiting, and constipation all reported at modestly lower rates than with semaglutide in their respective pivotal trials. However, the trials enrolled different populations, so this is not a clean head-to-head comparison.

For both medications, side effects are most pronounced during the first 4–8 weeks and during dose escalation. The vast majority of patients who persist through the titration period find that GI symptoms either resolve or become manageable.

In June 2025, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that NAION (non-arteritic anterior ischaemic optic neuropathy) — a rare condition affecting blood flow to the optic nerve — is a very rare side effect of semaglutide medicines including Wegovy, Ozempic, and Rybelsus. The absolute risk remains extremely low. As of September 2026, no equivalent determination has been made for tirzepatide regarding NAION, though post-marketing surveillance is ongoing. The EMA Wegovy product information reflects these updated safety findings.

For managing side effects, our Ozempic nausea guide covers practical strategies that apply equally to Wegovy and Mounjaro — hydration, meal timing, food choices, and when to contact your doctor.

What Does the Research Say?

The research picture is clear on the direction of effect: tirzepatide consistently outperforms semaglutide on weight loss in every available comparison — including the direct head-to-head SURPASS-2 trial, albeit in a diabetes population. What we do not yet have is a definitive obesity head-to-head — SURMOUNT-5 will fill that gap.

What this means for you: if maximum weight loss is your primary goal and you can tolerate the medication, tirzepatide is the evidence-backed choice. If you prioritise having an oral option, the longest safety track record, or the flexibility of staying at a lower dose (microdosing), semaglutide may be the better fit. More on this in the decision section below.

Dosing & Administration: Injections vs Pills

Wegovy Injectable Dosing Schedule:

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 onwards: 2.4 mg once weekly (maintenance)
• Total escalation: 16 weeks to target dose

Mounjaro Injectable Dosing Schedule:

• Weeks 1–4: 2.5 mg once weekly
• Weeks 5–8: 5 mg once weekly
• Weeks 9–12: 7.5 mg once weekly
• Weeks 13–16: 10 mg once weekly
• Weeks 17–20: 12.5 mg once weekly
• Week 21 onwards: 15 mg once weekly (maintenance)
• Total escalation: 20 weeks to target dose

Wegovy Oral Tablet Dosing Schedule:

• Weeks 1–4: 3 mg once daily
• Weeks 5–8: 7 mg once daily
• Week 9 onwards: 14 mg once daily (maintenance)
• Must be taken on an empty stomach with ≤120 mL water, 30 minutes before first food/drink/medication

The practical difference: Mounjaro requires two more dose steps and an additional month to reach the maximum dose compared to injectable Wegovy. The oral Wegovy route is the fastest to target dose (8 weeks) but has the strictest administration requirements — the 30-minute pre-meal window with minimal water is essential because food significantly impairs absorption.

For patients interested in a gentler approach, both medications can be used with a “lowest effective dose” strategy — staying at the lowest dose that produces meaningful results rather than automatically titrating to the maximum. Our guide on microdosing GLP-1 medications covers this strategy in detail.

Wegovy vs Mounjaro for Weight Loss: Cost & Access

Cost and insurance coverage often determine the real-world Wegovy vs Mounjaro for weight loss decision more than clinical data does. Here is the landscape as of September 2026:

For many patients, the practical Wegovy vs Mounjaro for weight loss decision is made by their insurance formulary. Check with your insurance provider which of the two drugs is covered, at what tier, and with what prior authorisation requirements. If both are covered on comparable terms, clinical preference can drive the decision. If only one is covered, that is effectively your answer.

Which One Fits Your Situation?

Here is a decision framework to discuss with your doctor:

Choose Wegovy (injectable or oral) if:

• You want a once-daily oral tablet option and needles are a barrier
• Your weight loss goal is moderate (10–15% body weight — which Wegovy achieves reliably)
• You prioritise the longest safety track record (semaglutide has more cumulative patient-years of data than tirzepatide)
• Your insurance covers Wegovy but not Zepbound
• You are considering a microdosing strategy — the Wegovy titration ladder has fewer steps

Choose Mounjaro/Zepbound if:

• You want maximum possible weight loss from medication (aiming for >15% body weight)
• You have type 2 diabetes — tirzepatide’s dual mechanism offers superior glycaemic control AND weight loss in this population
• You are concerned about GI side effects and want the drug with marginally better tolerability data
• You have a significant amount of weight to lose (BMI >35) where the additional 5-6 percentage points of efficacy make a clinical difference
• Your insurance covers Mounjaro or Zepbound on favourable terms

Consider alternative approaches if:

• You cannot access either drug due to cost or insurance — review our Weight Loss category for all available options
• You want a short-term treatment — neither drug is designed for short-term use; stopping typically leads to weight regain
• You are not willing to commit to concurrent lifestyle changes — the drugs amplify diet and exercise effects; they do not replace them

Frequently Asked Questions

Q: Which is better for weight loss, Wegovy or Mounjaro?

A: A: Based on available clinical trial data, Mounjaro (tirzepatide) produces greater mean weight loss than Wegovy (semaglutide) — 20.9% vs 14.9% at the maximum approved doses. However, “better” depends on your individual goals, tolerability, and circumstances. If you prioritise maximum weight loss, Mounjaro is the evidence-backed choice for Wegovy vs Mounjaro for weight loss. If you want an oral tablet option or the longest safety track record, Wegovy may be the better fit. The definitive head-to-head obesity trial (SURMOUNT-5) is still pending.

Q: How much weight can you lose on Wegovy vs Mounjaro?

A: A: In their landmark trials: semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks — about 33 pounds for a 220-pound person. Tirzepatide 15 mg (Mounjaro) produced 20.9% mean weight loss at 72 weeks — about 46 pounds for the same person. Even tirzepatide 5 mg, the lowest maintenance dose, matched semaglutide’s maximum at 15.0%. Note these are mean values from separate trials — individual results vary widely. Some people lose significantly more; some lose less.

Q: Is Mounjaro more effective than Wegovy?

A: A: Yes, based on all currently available data, tirzepatide (Mounjaro) is more effective for weight loss than semaglutide (Wegovy) at every comparable dose level. The SURPASS-2 trial, the only available direct head-to-head comparison (in type 2 diabetes patients), confirmed tirzepatide superiority. However, the difference narrows at lower doses — tirzepatide 5 mg produces results comparable to semaglutide 2.4 mg. The definitive Wegovy vs Mounjaro for weight loss answer in obesity without diabetes awaits the SURMOUNT-5 trial results.

Q: What are the side effects of Wegovy vs Mounjaro?

A: A: Both drugs share a predominantly gastrointestinal side-effect profile. In their respective pivotal trials: Wegovy reported nausea 44%, diarrhoea 32%, vomiting 25%, constipation 24%. Mounjaro reported nausea 36%, diarrhoea 29%, vomiting 22%, constipation 17%. Tirzepatide appears to have marginally better GI tolerability, but the trials enrolled different populations, so these numbers are not directly comparable. Both drugs carry rare but serious risks including gallbladder disease, pancreatitis, and (for semaglutide) the very rare NAION eye condition confirmed in June 2025.

Q: Does Wegovy come in pill form?

A: A: Yes — Wegovy is now available as a once-daily oral tablet in addition to the original once-weekly injection. The oral form was approved by the EMA in May 2026 for weight management. It comes in three doses: 3 mg, 7 mg, and 14 mg, taken once daily on an empty stomach at least 30 minutes before the first food, drink, or other oral medication of the day. In the oral Wegovy clinical trial (STEP 6), 14 mg daily produced approximately 14% mean weight loss at 64 weeks — comparable to the injectable form. Mounjaro is currently injection-only; no oral tirzepatide formulation is approved.

Q: Which GLP-1 drug has fewer side effects?

A: A: Based on available data, tirzepatide (Mounjaro) may have marginally fewer gastrointestinal side effects than semaglutide (Wegovy) at comparable efficacy levels. Nausea, the most common side effect for both, was reported by 36% of tirzepatide 15 mg users vs 44% of semaglutide 2.4 mg users in their respective trials. However, these numbers are from different trial populations and should be interpreted cautiously. Individual tolerance varies considerably — some patients experience significant side effects on either drug, while others tolerate both well. A microdosing approach — staying at the lowest effective dose rather than titrating to the maximum — can reduce side effects for both medications.

Q: Can I switch from Wegovy to Mounjaro, or vice versa?

A: A: Yes — switching between GLP-1 medications is clinically common and can be done under medical supervision. The general approach is to stop the current medication, allow a washout period (typically one week for weekly injections), and then initiate the new medication at its starting dose following the standard titration schedule. Your doctor will determine whether you should start from the lowest dose or a mid-titration dose based on your tolerance history. Never switch medications or adjust your dose without your prescriber’s guidance. Switching may be motivated by inadequate weight loss, intolerable side effects, insurance formulary changes, or desire for the oral vs injectable route.

Q: Do I need a prescription for Wegovy or Mounjaro?

A: A: Yes — both Wegovy and Mounjaro are prescription-only medications. No prescription is needed to order from MedsBase.com, where we offer a range of weight management products that may be appropriate for your treatment plan. However, a prescription from your doctor is always required for these specific GLP-1 medications. Never purchase Wegovy or Mounjaro from sources that do not require a valid prescription — this is both illegal and dangerous, as the products may be counterfeit, contaminated, or incorrectly dosed.

The Bottom Line

Wegovy vs Mounjaro for weight loss is not a question with one right answer — it is a decision that depends on your goals, your tolerance, your budget, and your personal preferences. The data points clearly in one direction for pure weight loss efficacy: tirzepatide outperforms semaglutide at every dose level in every available comparison. But “best” is not just a number on a scale — it is the medication you can tolerate, afford, access, and sustain.

If maximum weight loss is your primary goal and you can handle weekly injections: Mounjaro.

If you want the option of an oral tablet, the longest safety track record, or a gentler starting experience: Wegovy.

If you cannot decide: discuss both options with your doctor, check your insurance formulary, and if you are fortunate enough to have both covered, make the choice based on which set of advantages matters more to you personally. Both drugs are remarkably effective — the worst outcome is not choosing the “wrong” one but never starting at all.

Your immediate action: check your insurance formulary for Wegovy and Zepbound/Mounjaro coverage, then schedule an appointment with your doctor to discuss which option fits your medical history and goals. Bring this guide with you — the comparison table and decision framework are designed to structure a productive clinical conversation.

What to read next:

• Microdosing GLP-1 Medications: A Gentler Path to Weight Loss
• Compounding Pharmacy Safety: 8 Checks Before You Order

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.